Animal Models of Psychosis: Current State and Future Directions

Current Behavioral Neuroscience Reports

Volumn 1, Issue 2, 2014, Pages 100-116

  Forrest, Alexandra D ^a   Coto, Carlos A ^a   Siegel, Steven J ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Animal model; Behavior; Electroencephalography; Pharmacological manipulation; Psychosis; Transgenic mice

Indexed keywords

EID: 84904666589     PISSN: None     EISSN: 21962979     Source Type: Journal    
DOI: 10.1007/s40473-014-0013-2     Document Type: Article

References (200)

1. van der Mast RC et al. Incidence of and preoperative predictors for delirium after cardiac surgery. J Psychosom Res. 1999;46(5):479–83.
2. Geyer MA, Markou A. Animal models of psychiatric disorders, Psychopharmacology: The 4th Generation of Progress, F.E. Bloom and D.J. Kupfer, Editors. 1995, Raven Press: New York, NY.
3. Turetsky BI et al. Neurophysiological endophenotypes of schizophrenia: the viability of selected candidate measures. Schizophr Bull. 2007;33(1):69–94.
4. Arad M, Weiner I. Disruption of latent inhibition induced by ovariectomy can be reversed by estradiol and clozapine as well as by co-administration of haloperidol with estradiol but not by haloperidol alone. Psychopharmacology (Berlin). 2009;206(4):731–40.
5. Arad M, Weiner I. Contrasting effects of increased and decreased dopamine transmission on latent inhibition in ovariectomized rats and their modulation by 17beta-estradiol: an animal model of menopausal psychosis? Neuropsychopharmacology. 2010;35(7):1570–82.
6. Hemsley DR. A simple (or simplistic?) cognitive model for schizophrenia. Behav Res Ther. 1993;31(7):633–45.
7. Gray NS, Snowden RJ. The relevance of irrelevance to schizophrenia. Neurosci Biobehav Rev. 2005;29(6):989–99.
8. Shannon HE et al. Muscarinic receptor agonists, like dopamine receptor antagonist antipsychotics, inhibit conditioned avoidance response in rats. J Pharmacol Exp Ther. 1999;290(2):901–7.
9. Wadenberg ML, Hicks PB. The conditioned avoidance response test re-evaluated: is it a sensitive test for the detection of potentially atypical antipsychotics? Neurosci Biobehav Rev. 1999;23(6):851–62.
10. Wadenberg MG et al. Antagonism at 5-HT(2A) receptors potentiates the effect of haloperidol in a conditioned avoidance response task in rats. Pharmacol Biochem Behav. 2001;68(3):363–70.
11. Shannon HE et al. Xanomeline, an M(1)/M(4) preferring muscarinic cholinergic receptor agonist, produces antipsychotic-like activity in rats and mice. Schizophr Res. 2000;42(3):249–59.
12. Siuciak JA et al. Inhibition of the striatum-enriched phosphodiesterase PDE10A: a novel approach to the treatment of psychosis. Neuropharmacology. 2006;51(2):386–96.
13. Frith CD, Done DJ. Stereotyped responding by schizophrenic patients on a two-choice guessing task. Psychol Med. 1983;13(4):779–86.
14. Brady KT et al. Cocaine-induced psychosis. J Clin Psychiatry. 1991;52(12):509–12.
15. Robertson A, MacDonald C. Atypical neuroleptics clozapine and thioridazine enhance amphetamine-induced stereotypy. Pharmacol Biochem Behav. 1984;21(1):97–101.
16. Murray TF, Horita A. Phencyclidine-induced stereotyped behavior in rats: dose response effects and antagonism by neuroleptics. Life Sci. 1979;24(24):2217–25.
17. Fetsko LA, Xu R, Wang YY. Alterations in D1/D2 synergism may account for enhanced stereotypy and reduced climbing in mice lacking dopamine D2L receptor. Brain Res. 2003;967(1–2):191–200.
18. Nunes EA et al. Effects of pregabalin on behavioral alterations induced by ketamine in rats. Rev Bras Psiquiatr. 2012;34(3):329–33.
19. Martin RS et al. Effects of cannabinoid receptor ligands on psychosis-relevant behavior models in the rat. Psychopharmacology (Berlin). 2003;165(2):128–35.
20. Andine P et al. Characterization of MK-801-induced behavior as a putative rat model of psychosis. J Pharmacol Exp Ther. 1999;290(3):1393–408.
21. Waters KA et al. Effects of the selective 5-HT7 receptor antagonist SB-269970 in animal models of psychosis and cognition. Behav Brain Res. 2012;228(1):211–8.
22. Atkins AL et al. Stereotypic behaviors in mice selectively bred for high and low methamphetamine-induced stereotypic chewing. Psychopharmacology (Berlin). 2001;157(1):96–104.
23. Hitri A et al. Differentiation between MK-801- and apomorphine-induced stereotyped behaviors in mice. Clin Neuropharmacol. 1993;16(3):220–36.
24. Gattaz WF, Schummer B, Behrens S. Effects of zotepine, haloperidol and clozapine on MK-801-induced stereotypy and locomotion in rats. J Neural Transm Gen Sect. 1994;96(3):227–32.
25. Burris KD et al. Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J Pharmacol Exp Ther. 2002;302(1):381–9.
26. Machado MS et al. An organic selenium compound attenuates apomorphine-induced stereotypy in mice. Neurosci Lett. 2006;410(3):198–202.
27. Powell SB, Zhou X, Geyer MA. Prepulse inhibition and genetic mouse models of schizophrenia. Behav Brain Res. 2009;204(2):282–94.
28. Gerber DJ et al. Hyperactivity, elevated dopaminergic transmission, and response to amphetamine in M1 muscarinic acetylcholine receptor-deficient mice. Proc Natl Acad Sci U S A. 2001;98(26):15312–7.
29. Rodvelt KR et al. Ketamine induces hyperactivity in rats and hypersensitivity to nicotine in rat striatal slices. Pharmacol Biochem Behav. 2008;91(1):71–6.
30. Gray L et al. Role of muscarinic receptors in the activity of N-desmethylclozapine: reversal of hyperactivity in the phospholipase C knockout mouse. Behav Pharmacol. 2008;19(5–6):543–7.
31. de Bartolomeis A, Fiore G, Iasevoli F. Dopamine-glutamate interaction and antipsychotics mechanism of action: implication for new pharmacological strategies in psychosis. Curr Pharm Des. 2005;11(27):3561–94.
32. Stone JM et al. Altered relationship between hippocampal glutamate levels and striatal dopamine function in subjects at ultra high risk of psychosis. Biol Psychiatry. 2010;68(7):599–602.
33. Seeman P. All roads to schizophrenia lead to dopamine supersensitivity and elevated dopamine D2(high) receptors. CNS Neurosci Ther. 2011;17(2):118–32.
34. Kitahama K, Valatx JL. Strain differences in amphetamine sensitivity in mice. II. Overcompensation of paradoxical sleep after deprivation in two C57 strains. Psychopharmacology (Berlin). 1979;66(3):291–5.
35. Marona-Lewicka D, Nichols CD, Nichols DE. An animal model of schizophrenia based on chronic LSD administration: old idea, new results. Neuropharmacology. 2011;61(3):503–12.
36. Wieronska JM et al. The GABA B receptor agonist CGP44532 and the positive modulator GS39783 reverse some behavioural changes related to positive syndromes of psychosis in mice. Br J Pharmacol. 2011;163(5):1034–47.
37. Geyer MA, McIlwain KL, Paylor R. Mouse genetic models for prepulse inhibition: an early review. Mol Psychiatry. 2002;7(10):1039–53.
38. Aasen I, Kolli L, Kumari V. Sex effects in prepulse inhibition and facilitation of the acoustic startle response: implications for pharmacological and treatment studies. J Psychopharmacol. 2005;19(1):39–45.
39. Ellenbroek BA, Cools AR. Animal models with construct validity for schizophrenia. Behav Pharmacol. 1990;1(6):469–90.
40. Lubow RE. Construct validity of the animal latent inhibition model of selective attention deficits in schizophrenia. Schizophr Bull. 2005;31(1):139–53.
41. Weiner I. The "two-headed" latent inhibition model of schizophrenia: modeling positive and negative symptoms and their treatment. Psychopharmacology (Berlin). 2003;169(3–4):257–97.
42. Weiner I, Arad M. Using the pharmacology of latent inhibition to model domains of pathology in schizophrenia and their treatment. Behav Brain Res. 2009;204(2):369–86.
43. Dietrich A, Kanso R. A review of EEG, ERP, and neuroimaging studies of creativity and insight. Psychol Bull. 2010;136(5):822–48.
44. Connolly PM et al. The effects of ketamine vary among inbred mouse strains and mimic schizophrenia for the P80, but not P20 or N40 auditory ERP components. Neurochem Res. 2004;29(6):1179–88.
45. Siegel SJ et al. Effects of strain, novelty, and NMDA blockade on auditory-evoked potentials in mice. Neuropsychopharmacology. 2003;28(4):675–82.
46. Maxwell CR et al. Effects of chronic olanzapine and haloperidol differ on the mouse N1 auditory evoked potential. Neuropsychopharmacology. 2004;29(4):739–46.
47. Stevens KE, Wear KD. Normalizing effects of nicotine and a novel nicotinic agonist on hippocampal auditory gating in two animal models. Pharmacol Biochem Behav. 1997;57(4):869–74.
48. Simosky JK, Freedman R, Stevens KE. Olanzapine improves deficient sensory inhibition in DBA/2 mice. Brain Res. 2008;1233:129–36.
49. Simosky JK et al. Clozapine improves deficient inhibitory auditory processing in DBA/2 mice, via a nicotinic cholinergic mechanism. Psychopharmacology (Berlin). 2003;165(4):386–96.
50. Maxwell CR et al. Ketamine produces lasting disruptions in encoding of sensory stimuli. J Pharmacol Exp Ther. 2006;316(1):315–24.
51. Metzger KL et al. Effects of nicotine vary across two auditory evoked potentials in the mouse. Biol Psychiatry. 2007;61(1):23–30.
52. Rudnick ND et al. Role of beta2-containing nicotinic acetylcholine receptors in auditory event-related potentials. Psychopharmacology (Berlin). 2009;202(4):745–51.
53. Bomba MD, Pang EW. Cortical auditory evoked potentials in autism: a review. Int J Psychophysiol. 2004;53(3):161–9.
54. Ulanovsky N et al. Multiple time scales of adaptation in auditory cortex neurons. J Neurosci. 2004;24(46):10440–53.
55. Naatanen R. Mismatch negativity (MMN): perspectives for application. Int J Psychophysiol. 2000;37(1):3–10.
56. Alho K. Cerebral generators of mismatch negativity (MMN) and its magnetic counterpart (MMNm) elicited by sound changes. Ear Hear. 1995;16(1):38–51.
57. Gomot M et al. Maturation of frontal and temporal components of mismatch negativity (MMN) in children. Neuroreport. 2000;11(14):3109–12.
58. Fischer JE, Stallmach T, Fanconi S. Adrenal crisis presenting as hypoglycemic coma. Intensive Care Med. 2000;26(1):105–8.
59. Garrido MI et al. The mismatch negativity: a review of underlying mechanisms. Clin Neurophysiol. 2009;120(3):453–63.
60. Polich J. Updating P300: an integrative theory of P3a and P3b. Clin Neurophysiol. 2007;118(10):2128–48.
61. Amann LC et al. In vitro-in vivo correlations of scalable PLGA-risperidone implants for the treatment of schizophrenia. Pharm Res. 2010;27(8):1730–7.
62. Gandal MJ et al. Gamma synchrony: towards a translational biomarker for the treatment-resistant symptoms of schizophrenia. Neuropharmacology. 2012;62(3):1504–18.
63. Gandal MJ et al. A novel electrophysiological model of chemotherapy-induced cognitive impairments in mice. Neuroscience. 2008;157(1):95–104.
64. Jongsma ML et al. Expectancy effects on omission evoked potentials in musicians and non-musicians. Psychophysiology. 2005;42(2):191–201.
65. Linden DE. The p300: where in the brain is it produced and what does it tell us? Neuroscientist. 2005;11(6):563–76.
66. Soltani M, Knight RT. Neural origins of the P300. Crit Rev Neurobiol. 2000;14(3–4):199–224.
67. Birnbaum R, Weinberger DR. Functional neuroimaging and schizophrenia: a view towards effective connectivity modeling and polygenic risk. Dialogues Clin Neurosci. 2013;15(3):279–89.
68. Talamini LM et al. Methylazoxymethanol acetate-induced abnormalities in the entorhinal cortex of the rat; parallels with morphological findings in schizophrenia. Brain Res. 1998;789(2):293–306.
69. Gourevitch R et al. Working memory deficits in adult rats after prenatal disruption of neurogenesis. Behav Pharmacol. 2004;15(4):287–92.
70. Fiore M et al. Long-lasting effects of prenatal MAM treatment on water maze performance in rats: associations with altered brain development and neurotrophin levels. Neurotoxicol Teratol. 2002;24(2):179–91.
71. Featherstone RE, Kapur S, Fletcher PJ. The amphetamine-induced sensitized state as a model of schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2007;31(8):1556–71.
72. Featherstone RE et al. Gestational methylazoxymethanol acetate treatment impairs select cognitive functions: parallels to schizophrenia. Neuropsychopharmacology. 2007;32(2):483–92.
73. Moore H et al. A neurobehavioral systems analysis of adult rats exposed to methylazoxymethanol acetate on E17: implications for the neuropathology of schizophrenia. Biol Psychiatry. 2006;60(3):253–64.
74. Francois J et al. Selective reorganization of GABAergic transmission in neonatal ventral hippocampal-lesioned rats. Int J Neuropsychopharmacol. 2009;12(8):1097–110.
75. Zamberletti E et al. Chronic blockade of CB(1) receptors reverses startle gating deficits and associated neurochemical alterations in rats reared in isolation. Br J Pharmacol. 2012;167(8):1652–64.
76. Zamberletti E et al. Long-lasting recovery of psychotic-like symptoms in isolation-reared rats after chronic but not acute treatment with the cannabinoid antagonist AM251. Int J Neuropsychopharmacol. 2012;15(2):267–80.
77. Niwa M, et al. Adolescent stress-induced epigenetic control of dopaminergic neurons via glucocorticoids. Science, 2013. 339 (6117): 335-339.
78. Geyer MA et al. Isolation rearing of rats produces a deficit in prepulse inhibition of acoustic startle similar to that in schizophrenia. Biol Psychiatry. 1993;34(6):361–72.
79. Koda K et al. Galantamine and donepezil differently affect isolation rearing-induced deficits of prepulse inhibition in mice. Psychopharmacology (Berlin). 2008;196(2):293–301.
80. Moller M et al. Social isolation rearing induces mitochondrial, immunological, neurochemical and behavioural deficits in rats, and is reversed by clozapine or N-acetyl cysteine. Brain Behav Immun. 2013;30:156–67.
81. McIntosh AL et al. The atypical antipsychotic risperidone reverses the recognition memory deficits induced by post-weaning social isolation in rats. Psychopharmacology (Berlin). 2013;228(1):31–42.
82. Lapiz MD et al. Influence of postweaning social isolation in the rat on brain development, conditioned behaviour and neurotransmission. Ross Fiziol Zh Im I M Sechenova. 2001;87(6):730–51.
83. Watson DJ et al. Blockade of dopamine D(3) but not D(2) receptors reverses the novel object discrimination impairment produced by post-weaning social isolation: implications for schizophrenia and its treatment. Int J Neuropsychopharmacol. 2012;15(4):471–84.
84. Koike H et al. Behavioral abnormality and pharmacologic response in social isolation-reared mice. Behav Brain Res. 2009;202(1):114–21.
85. Colaianna M et al. Neuroendocrine profile in a rat model of psychosocial stress: relation to oxidative stress. Antioxid Redox Signal. 2013;18(12):1385–99.
86. Schiavone S et al. NADPH oxidase elevations in pyramidal neurons drive psychosocial stress-induced neuropathology. Transl Psychiatry. 2012;2:e111.
87. Muchimapura S et al. Isolation rearing in the rat disrupts the hippocampal response to stress. Neuroscience. 2002;112(3):697–705.
88. Turnock-Jones JJ et al. Increased expression of the NR2A NMDA receptor subunit in the prefrontal cortex of rats reared in isolation. Synapse. 2009;63(10):836–46.
89. Sestito RS et al. Effect of isolation rearing on the expression of AMPA glutamate receptors in the hippocampal formation. J Psychopharmacol. 2011;25(12):1720–9.
90. King MV et al. Increased dopamine D2High receptors in rats reared in social isolation. Synapse. 2009;63(6):476–83.
91. Ago Y, Matsuda T. Brain microdialysis of isolation-reared mice under freely-moving conditions. Nihon Yakurigaku Zasshi. 2003;122(2):135–40.
92. Lim AL, Taylor DA, Malone DT. A two-hit model: behavioural investigation of the effect of combined neonatal MK-801 administration and isolation rearing in the rat. J Psychopharmacol. 2012;26(9):1252–64.
93. Suer C, Dolu N, Ozesmi C. The effect of immobilization stress on sensory gating in mice. Int J Neurosci. 2004;114(1):55–65.
94. Matrisciano F et al. Epigenetic modifications of GABAergic interneurons are associated with the schizophrenia-like phenotype induced by prenatal stress in mice. Neuropharmacology. 2013;68:184–94.
95. Koenig JI et al. Prenatal exposure to a repeated variable stress paradigm elicits behavioral and neuroendocrinological changes in the adult offspring: potential relevance to schizophrenia. Behav Brain Res. 2005;156(2):251–61.
96. Lee PR et al. Prenatal stress generates deficits in rat social behavior: Reversal by oxytocin. Brain Res. 2007;1156:152–67.
97. Holloway T et al. Prenatal stress induces schizophrenia-like alterations of serotonin 2A and metabotropic glutamate 2 receptors in the adult offspring: role of maternal immune system. J Neurosci. 2013;33(3):1088–98.
98. Blomstrom A, et al. Hospital admission with infection during childhood and risk for psychotic illness—A population-based cohort study. Schizophr Bull, 2013.
99. Kroll JL. New directions in the conceptualization of psychotic disorders. Curr Opin Psychiatry. 2007;20(6):573–7.
100. Lindley SE, Carlson E, Sheikh J. Psychotic symptoms in posttraumatic stress disorder. CNS Spectr. 2000;5(9):52–7.
101. Clarke MC et al. Sudden death of father or sibling in early childhood increases risk for psychotic disorder. Schizophr Res. 2013;143(2–3):363–6.
102. Rubino T, Parolaro D. Cannabis abuse in adolescence and the risk of psychosis: A brief review of the preclinical evidence. Prog Neuropsychopharmacol Biol Psychiatry, 2013.
103. Miettunen J et al. Association of cannabis use with prodromal symptoms of psychosis in adolescence. Br J Psychiatry. 2008;192(6):470–1.
104. Seeman P et al. Brain receptors for antipsychotic drugs and dopamine: direct binding assays. Proc Natl Acad Sci U S A. 1975;72(11):4376–80.
105. Srisurapanont M, Kittiratanapaiboon P, Jarusuraisin N. Treatment for amphetamine psychosis. Cochrane Database Syst Rev. 2001;4, CD003026.
106. Yui K et al. Neurobiological basis of relapse prediction in stimulant-induced psychosis and schizophrenia: the role of sensitization. Mol Psychiatry. 1999;4(6):512–23.
107. Angrist BM, Gershon S. The phenomenology of experimentally induced amphetamine psychosis—preliminary observations. Biol Psychiatry. 1970;2(2):95–107.
108. Levy AD et al. Repeated exposure to cocaine produces long-lasting deficits in the serotonergic stimulation of prolactin and renin, but not adrenocorticotropin secretion. Eur J Pharmacol. 1993;241(2–3):275–8.
109. Stevens KE, Fuller LL, Rose GM. Dopaminergic and noradrenergic modulation of amphetamine-induced changes in auditory gating. Brain Res. 1991;555(1):91–8.
110. Stevens KE et al. Effects of neonatal dopamine depletion on sensory inhibition in the rat. Pharmacol Biochem Behav. 1996;53(4):817–23.
111. Maxwell CR et al. Phosphodiesterase inhibitors: a novel mechanism for receptor-independent antipsychotic medications. Neuroscience. 2004;129(1):101–7.
112. de Bruin NM et al. Differential effects of ketamine on gating of auditory evoked potentials and prepulse inhibition in rats. Psychopharmacology (Berlin). 1999;142(1):9–17.
113. Adler LE et al. Modulation of the gating of auditory evoked potentials by norepinephrine: pharmacological evidence obtained using a selective neurotoxin. Biol Psychiatry. 1988;24(2):179–90.
114. Segal DS, Kuczenski R. Escalating dose-binge treatment with methylphenidate: role of serotonin in the emergent behavioral profile. J Pharmacol Exp Ther. 1999;291(1):19–30.
115. Depatie L, Lal S. Apomorphine and the dopamine hypothesis of schizophrenia: a dilemma? J Psychiatry Neurosci. 2001;26(3):203–20.
116. Depoortere R et al. Apomorphine-induced emesis in dogs: differential sensitivity to established and novel dopamine D2/5-HT(1A) antipsychotic compounds. Eur J Pharmacol. 2008;597(1–3):34–8.
117. Dias FR et al. Opposite effects of low versus high dose haloperidol treatments on spontaneous and apomorphine induced motor behavior: evidence that at a very low dose haloperidol acts as an indirect dopamine agonist. Behav Brain Res. 2012;229(1):153–9.
118. Hikida T et al. Dominant-negative DISC1 transgenic mice display schizophrenia-associated phenotypes detected by measures translatable to humans. Proc Natl Acad Sci U S A. 2007;104(36):14501–6.
119. Jaaro-Peled H et al. Subcortical dopaminergic deficits in a DISC1 mutant model: a study in direct reference to human molecular brain imaging. Hum Mol Genet. 2013;22(8):1574–80.
120. Porteous DJ et al. The genetics and biology of DISC1—an emerging role in psychosis and cognition. Biol Psychiatry. 2006;60(2):123–31.
121. Axelrod J, Senoh S, Witkop B. O-Methylation of catechol amines in vivo. J Biol Chem. 1958;233(3):697–701.
122. Goldberg TE, Weinberger DR. Genes and the parsing of cognitive processes. Trends Cogn Sci. 2004;8(7):325–35.
123. Lachman HM et al. Human catechol-O-methyltransferase pharmacogenetics: description of a functional polymorphism and its potential application to neuropsychiatric disorders. Pharmacogenetics. 1996;6(3):243–50.
124. Chen J et al. Functional analysis of genetic variation in catechol-O-methyltransferase (COMT): effects on mRNA, protein, and enzyme activity in postmortem human brain. Am J Hum Genet. 2004;75(5):807–21.
125. Cao YA et al. Nicotine normalizes event related potentials in COMT-Val-tg mice and increases gamma and theta spectral density. Behav Neurosci. 2012;126(2):332–43.
126. Shaikh M et al. Do COMT, BDNF and NRG1 polymorphisms influence P50 sensory gating in psychosis? Psychol Med. 2011;41(2):263–76.
127. Papaleo F, et al. Epistatic interaction between COMT and DTNBP1 modulates prefrontal function in mice and in humans. Mol Psychiatry, 2013.
128. Tan HY et al. Epistatic interactions of AKT1 on human medial temporal lobe biology and pharmacogenetic implications. Mol Psychiatry. 2012;17(10):1007–16.
129. Nixon DC et al. Interactive effects of DAOA (G72) and catechol-O-methyltransferase on neurophysiology in prefrontal cortex. Biol Psychiatry. 2011;69(10):1006–8.
130. Sei Y et al. Epistatic and functional interactions of catechol-o-methyltransferase (COMT) and AKT1 on neuregulin1-ErbB signaling in cell models. PLoS One. 2010;5(5):e10789.
131. Tan HY et al. Catechol-O-methyltransferase Val158Met modulation of prefrontal-parietal-striatal brain systems during arithmetic and temporal transformations in working memory. J Neurosci. 2007;27(49):13393–401.
132. Nicodemus KK et al. Evidence for statistical epistasis between catechol-O-methyltransferase (COMT) and polymorphisms in RGS4, G72 (DAOA), GRM3, and DISC1: influence on risk of schizophrenia. Hum Genet. 2007;120(6):889–906.
133. Gould TJ et al. Sensorimotor gating deficits in transgenic mice expressing a constitutively active form of Gs alpha. Neuropsychopharmacology. 2004;29(3):494–501.
134. Wand G et al. The cAMP-protein kinase A signal transduction pathway modulates ethanol consumption and sedative effects of ethanol. J Neurosci. 2001;21(14):5297–303.
135. Numakawa T et al. Evidence of novel neuronal functions of dysbindin, a susceptibility gene for schizophrenia. Hum Mol Genet. 2004;13(21):2699–708.
136. Talbot K et al. Dysbindin-1 is reduced in intrinsic, glutamatergic terminals of the hippocampal formation in schizophrenia. J Clin Invest. 2004;113(9):1353–63.
137. Vilella E et al. Association of schizophrenia with DTNBP1 but not with DAO, DAOA, NRG1 and RGS4 nor their genetic interaction. J Psychiatr Res. 2008;42(4):278–88.
138. Talbot K. The sandy (sdy) mouse: a dysbindin-1 mutant relevant to schizophrenia research. Prog Brain Res. 2009;179:87–94.
139. Tang J et al. Dysbindin-1 in dorsolateral prefrontal cortex of schizophrenia cases is reduced in an isoform-specific manner unrelated to dysbindin-1 mRNA expression. Hum Mol Genet. 2009;18(20):3851–63.
140. Ji Y et al. Role of dysbindin in dopamine receptor trafficking and cortical GABA function. Proc Natl Acad Sci U S A. 2009;106(46):19593–8.
141. Chen XW et al. DTNBP1, a schizophrenia susceptibility gene, affects kinetics of transmitter release. J Cell Biol. 2008;181(5):791–801.
142. Nagai T et al. Dysfunction of dopamine release in the prefrontal cortex of dysbindin deficient sandy mice: an in vivo microdialysis study. Neurosci Lett. 2010;470(2):134–8.
143. Jentsch JD et al. Dysbindin modulates prefrontal cortical glutamatergic circuits and working memory function in mice. Neuropsychopharmacology. 2009;34(12):2601–8.
144. Talbot K et al. Dysbindin-1 is a synaptic and microtubular protein that binds brain snapin. Hum Mol Genet. 2006;15(20):3041–54.
145. Guo AY et al. The dystrobrevin-binding protein 1 gene: features and networks. Mol Psychiatry. 2009;14(1):18–29.
146. Feng YQ et al. Dysbindin deficiency in sandy mice causes reduction of snapin and displays behaviors related to schizophrenia. Schizophr Res. 2008;106(2–3):218–28.
147. Pae CU et al. DTNBP1 haplotype influences baseline assessment scores of schizophrenic in-patients. Neurosci Lett. 2008;440(2):150–4.
148. Corvin A et al. A dysbindin risk haplotype associated with less severe manic-type symptoms in psychosis. Neurosci Lett. 2008;431(2):146–9.
149. Becker A et al. Ketamine-induced changes in rat behaviour: A possible animal model of schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2003;27(4):687–700.
150. Umbricht D et al. Ketamine-induced deficits in auditory and visual context-dependent processing in healthy volunteers: implications for models of cognitive deficits in schizophrenia. Arch Gen Psychiatry. 2000;57(12):1139–47.
151. Oranje B et al. The effects of a sub-anaesthetic dose of ketamine on human selective attention. Neuropsychopharmacology. 2000;22(3):293–302.
152. Olney JW, Newcomer JW, Farber NB. NMDA receptor hypofunction model of schizophrenia. J Psychiatr Res. 1999;33(6):523–33.
153. Javitt DC. Glutamatergic theories of schizophrenia. Isr J Psychiatry Relat Sci. 2010;47(1):4–16.
154. Bickel S, Javitt DC. Neurophysiological and neurochemical animal models of schizophrenia: focus on glutamate. Behav Brain Res. 2009;204(2):352–62.
155. Ehrlichman RS et al. Deviance-elicited changes in event-related potentials are attenuated by ketamine in mice. J Cogn Neurosci. 2008;20(8):1403–14.
156. Heekeren K et al. Mismatch negativity generation in the human 5HT2A agonist and NMDA antagonist model of psychosis. Psychopharmacology (Berlin). 2008;199(1):77–88.
157. Deutsch SI, Hitri A. Measurement of an explosive behavior in the mouse, induced by MK-801, a PCP analogue. Clin Neuropharmacol. 1993;16(3):251–7.
158. Rogoz Z. Effect of co-treatment with mirtazapine and risperidone in animal models of the positive symptoms of schizophrenia in mice. Pharmacol Rep. 2012;64(6):1567–72.
159. Qi CT et al. Effect of GNTI, a kappa opioid receptor antagonist, on MK-801-induced hyperlocomotion and stereotypy in mice. Acta Pharmacol Sin. 2006;27(11):1401–8.
160. Harkin A et al. Modulation of MK-801-induced behaviour by noradrenergic agents in mice. Psychopharmacology (Berlin). 2001;154(2):177–88.
161. Hashimoto A et al. Mice lacking D-amino acid oxidase activity display marked attenuation of stereotypy and ataxia induced by MK-801. Brain Res. 2005;1033(2):210–5.
162. Ali SF, Newport GD, Bracha HS. Phencyclidine and (+)-MK-801-induced circling preference: correlation with monoamine levels in striatum of the rat brain. Neurotoxicol Teratol. 1994;16(4):335–42.
163. Mathe JM et al. Prazosin inhibits MK-801-induced hyperlocomotion and dopamine release in the nucleus accumbens. Eur J Pharmacol. 1996;309(1):1–11.
164. Arai S et al. Involvement of pallidotegmental neurons in methamphetamine- and MK-801-induced impairment of prepulse inhibition of the acoustic startle reflex in mice: reversal by GABAB receptor agonist baclofen. Neuropsychopharmacology. 2008;33(13):3164–75.
165. Pietraszek M et al. mGluR5, but not mGluR1, antagonist modifies MK-801-induced locomotor activity and deficit of prepulse inhibition. Neuropharmacology. 2005;49(1):73–85.
166. Pinault D. N-methyl d-aspartate receptor antagonists ketamine and MK-801 induce wake-related aberrant gamma oscillations in the rat neocortex. Biol Psychiatry. 2008;63(8):730–5.
167. Saunders JA, Gandal MJ, Siegel SJ. NMDA antagonists recreate signal-to-noise ratio and timing perturbations present in schizophrenia. Neurobiol Dis. 2012;46(1):93–100.
168. Bujas-Bobanovic M et al. Blockade of phencyclidine-induced effects by a nitric oxide donor. Br J Pharmacol. 2000;130(5):1005–12.
169. Volf N, Hu G, Li M. Iptakalim preferentially decreases nicotine-induced hyperlocomotion in phencyclidine-sensitized rats: A potential dual action against nicotine addiction and psychosis. Clin Psychopharmacol Neurosci. 2012;10(3):168–79.
170. Hackler EA et al. Selective potentiation of the metabotropic glutamate receptor subtype 2 blocks phencyclidine-induced hyperlocomotion and brain activation. Neuroscience. 2010;168(1):209–18.
171. Abekawa T et al. Effects of NRA0045, a novel potent antagonist at dopamine D4, 5-HT2A, and alpha1 adrenaline receptors, and NRA0160, a selective D4 receptor antagonist, on phencyclidine-induced behavior and glutamate release in rats. Psychopharmacology (Berlin). 2003;169(3–4):247–56.
172. Sircar R, Soliman KF. Effects of postnatal PCP treatment on locomotor behavior and striatal D2 receptor. Pharmacol Biochem Behav. 2003;74(4):943–52.
173. Haller J et al. Cannabinoid CB1 receptor dependent effects of the NMDA antagonist phencyclidine in the social withdrawal model of schizophrenia. Behav Pharmacol. 2005;16(5–6):415–22.
174. Javitt DC et al. Schizophrenia-like deficits in auditory P1 and N1 refractoriness induced by the psychomimetic agent phencyclidine (PCP). Clin Neurophysiol. 2000;111(5):833–6.
175. Ma J, Leung LS. Relation between hippocampal gamma waves and behavioral disturbances induced by phencyclidine and methamphetamine. Behav Brain Res. 2000;111(1–2):1–11.
176. Barros CS et al. Impaired maturation of dendritic spines without disorganization of cortical cell layers in mice lacking NRG1/ErbB signaling in the central nervous system. Proc Natl Acad Sci U S A. 2009;106(11):4507–12.
177. Bjarnadottir M et al. Neuregulin1 (NRG1) signaling through Fyn modulates NMDA receptor phosphorylation: differential synaptic function in NRG1+/- knock-outs compared with wild-type mice. J Neurosci. 2007;27(17):4519–29.
178. Gu Z et al. Regulation of NMDA receptors by neuregulin signaling in prefrontal cortex. J Neurosci. 2005;25(20):4974–84.
179. Hahn CG et al. Altered neuregulin 1-erbB4 signaling contributes to NMDA receptor hypofunction in schizophrenia. Nat Med. 2006;12(7):824–8.
180. Li B et al. The neuregulin-1 receptor erbB4 controls glutamatergic synapse maturation and plasticity. Neuron. 2007;54(4):583–97.
181. Ehrlichman RS et al. Neuregulin 1 transgenic mice display reduced mismatch negativity, contextual fear conditioning and social interactions. Brain Res. 2009;1294:116–27.
182. Mohn AR et al. Mice with reduced NMDA receptor expression display behaviors related to schizophrenia. Cell. 1999;98(4):427–36.
183. Yu Z et al. GABA transporter-1 deficiency confers schizophrenia-like behavioral phenotypes. PLoS One. 2013;8(7):e69883.
184. Llado-Pelfort L et al. 5-HT1A receptor agonists enhance pyramidal cell firing in prefrontal cortex through a preferential action on GABA interneurons. Cereb Cortex. 2012;22(7):1487–97.
185. Szabadics J et al. Excitatory effect of GABAergic axo-axonic cells in cortical microcircuits. Science. 2006;311(5758):233–5.
186. Gouzoulis-Mayfrank E et al. Psychological effects of (S)-ketamine and N, N-dimethyltryptamine (DMT): a double-blind, cross-over study in healthy volunteers. Pharmacopsychiatry. 2005;38(6):301–11.
187. Halberstadt AL, Geyer MA. Serotonergic hallucinogens as translational models relevant to schizophrenia. Int J Neuropsychopharmacol. 2013;16(10):2165–80.
188. Carhart-Harris RL et al. Psychiatry's next top model: cause for a re-think on drug models of psychosis and other psychiatric disorders. J Psychopharmacol. 2013;27(9):771–8.
189. Vollenweider FX et al. Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action. Neuroreport. 1998;9(17):3897–902.
190. Santini MA et al. Enhanced prefrontal serotonin 2A receptor signaling in the subchronic phencyclidine mouse model of schizophrenia. J Neurosci Res. 2013;91(5):634–41.
191. Trichard C et al. Binding of antipsychotic drugs to cortical 5-HT2A receptors: a PET study of chlorpromazine, clozapine, and amisulpride in schizophrenic patients. Am J Psychiatry. 1998;155(4):505–8.
192. Shapiro DA et al. Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology. 2003;28(8):1400–11.
193. Leysen JE et al. Risperidone: a novel antipsychotic with balanced serotonin-dopamine antagonism, receptor occupancy profile, and pharmacologic activity. J Clin Psychiatry. 1994;55(Suppl):5–12.
194. Martin P et al. Rodent data and general hypothesis: antipsychotic action exerted through 5-Ht2A receptor antagonism is dependent on increased serotonergic tone. J Neural Transm. 1998;105(4–5):365–96.
195. Nandra KS, Agius M. The differences between typical and atypical antipsychotics: the effects on neurogenesis. Psychiatr Danub. 2012;24 Suppl 1:S95–9.
196. Weiner DM et al. 5-hydroxytryptamine2A receptor inverse agonists as antipsychotics. J Pharmacol Exp Ther. 2001;299(1):268–76.
197. van den Buuse M et al. Altered N-methyl-D-aspartate receptor function in reelin heterozygous mice: male-female differences and comparison with dopaminergic activity. Prog Neuropsychopharmacol Biol Psychiatry. 2012;37(2):237–46.
198. Proitsi P et al. Association of serotonin and dopamine gene pathways with behavioral subphenotypes in dementia. Neurobiol Aging. 2012;33(4):791–803.
199. Luoni A et al. Behavioural and neuroplastic properties of chronic lurasidone treatment in serotonin transporter knockout rats. Int J Neuropsychopharmacol. 2013;16(6):1319–30.
200. Daws LC, Gould GG. Ontogeny and regulation of the serotonin transporter: providing insights into human disorders. Pharmacol Ther. 2011;131(1):61–79.